ABCL compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ABCLAbCellera Biologics Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ABCLAbCellera Biologics Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ABCL1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±15.4%▲+10.30%×0.67

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedABCL realized, solidLLY realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

ABCLAbCellera Biologics Inc.

11.61▲+4.28%

Mkt cap$3.4BRevenue$4MQ2 FY26Revenue$75MFY25

LLYELI Lilly & Co

1,367.16▲+0.18%

Regular sessionNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Regular sessionNov 6 '26

ABCLAbCellera Biologics Inc.

LLYELI Lilly & Co

11.61▲+4.28%

Price

1,367.16▲+0.18%

$3.4B

Mkt cap

$1.2T

Q2 FY26$4M

Revenue

$24.4BQ3 FY26

FY25$75M

Revenue

$65.2BFY25

ABCL11.61▲+4.28%vsLLY1,367.16▲+0.18%Regular sessionNov 6 '26